Your browser does not support inline frames or is currently configured not to display inline frames.

Your browser does not support inline frames or is currently configured not to display inline frames.

Your browser does not support inline frames or is currently configured not to display inline frames.

Cell Biosciences introduces kits for oncoprotein analysis

31 January 2009

Cell Biosciences, Inc., has launched its first kits for the analysis
of specific oncoproteins on the Firefly 3000 Protein Analysis System.
The new kits are optimized for characterization of proteins in the MEK
and ERK families, which play critical roles in cancer cell survival and
proliferation. Drug developers have targeted signaling via MEK and ERK
with a number of kinase inhibitor anticancer drugs.

The Firefly 3000 system is an ultrasensitive nanofluidic immunoassay
system designed to analyze extremely small biological samples.
Traditional protein analysis techniques can require as many as 100,000
cells, which generally precludes protein analysis in precious clinical
samples.

By using the new analysis kits on the Firefly 3000 system,
researchers can obtain detailed profiles of MEK and ERK signaling in as
few as 25 cells. Subtle effects of kinase inhibitor drugs on MEK and ERK
phosphorylation can be studied in cancer cells and solid tumor samples.

"We developed these oncoprotein analysis kits in response to strong
interest from our cancer research customers," said Wilhelm Lachnit,
Ph.D., Vice President of Research and Development. "They enable robust
analysis of MEK and ERK phosphoprotein signaling, and provide a unique
window into the specific actions of kinase inhibitor drugs in limited
samples."

Bookmark this page

Your browser does not support inline frames or is currently configured not to display inline frames.